Status: Not yet recruiting
A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: BrightPath Biotherapeutics Co., Ltd.Updated: Jul 1, 2026
Eligibility criteria
Diagnosis of Multiple Myeloma with relapsed or refractory disease. [+3]
Known active central nervous system (CNS) involvement or exhibits clinical signs... [+1]